In Vivo Testing For Réjuve “Continues” To Yield Positive Results

 

LEXINGTON, KY, December 9, 2014 Intralink Spine, Inc. (ILS) is pleased to announce long-term large-animal in vivo testing for the Réjuve agent continues to yield positive results.

 

“As of the 90 day post-procedure point (3 months) all sheep are healthy and showing no signs of trouble walking or infection.  This has been confirmed through observations by the Cincinnati Children's Hospital Medical Center (CCHMC) veterinary staff and by bloodwork done on all sheep at regular intervals.  White blood cell counts for the sheep are all within normal ranges indicating that there is no internal infection or elevated immune response that is not yet visible through normal observation”, states Matt Brown, Scientist at ILS.

 

The first phase of the in vivo testing being conducted at Cincinnati Children’s Hospital includes four sheep. Each animal is given two injections per disc in the annulus region. Treatment is applied to two alternating discs per animal.

 

According to Dr. Tom Hedman, CSO of Intralink Spine and a leading researcher in soft-tissue biomechanics, “Réjuve works in the same manner as the body’s natural response to heal instability and degradation of the spinal disc. The Réjuve device immediately strengthens and stabilizes the disc upon injection to reduce the pain of the patient and eliminate future episodes of debilitating back pain. This micro-invasive procedure can be performed on an outpatient basis and completed with just one injection treatment.”

 

About 80 percent of the adults in the U.S. experience significant back pain at some point in their life and most back pain sufferers find no relief. In fact, low back pain (LBP) is a challenging condition to treat and one of the most common health problems in the United States for a host of reasons including widespread obesity, an aging population, job related activities or inactivity, and smoking.  And, unlike Réjuve, most minimally invasive treatments being used today, such as steroid injections or nerve blocks, are temporary and palliative.   As a consequence, acute and chronic back pain continues to be a growing part of the US health landscape.

 

ILS is located on the University of Kentucky’s Coldstream Research Campus in the heart of the Kentucky Bluegrass Region. Coldstream provides ILS with a connection to students, researchers, and resources at the University of Kentucky.

© 2020 by Intralink-Spine Inc. 

Attention: The IDSD is not available for sale in the US, Canada, or EU. Clinical studies are being conducted In Australia.